TY - JOUR
T1 - Proton spectroscopy in asymptomatic HIV-infected adults
T2 - Initial results in a prospective cohort study
AU - Jarvik, Jeffrey G.
AU - Lenkinski, Robert E.
AU - Saykin, Andrew J.
AU - Jaans, Anna
AU - Frank, Ian
N1 - Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.
PY - 1996
Y1 - 1996
N2 - The purpose of our study was to determine whether proton magnetic resonance spectroscopy (MRS) could detect early brain involvement by human immunodeficiency virus (HIV). We recruited 19 asymptomatic HIV-infected patients, 9 with and 10 without a history of intravenous drug use (IDU), as well as 10 control subjects. All subjects had to have normal MR imaging to be enrolled. We identified the following peaks on proton MRS: n-acetyl aspartate, creatine, choline, and a conglomerate amino acid peak between 2.1 and 2.6 parts per million that we call the marker peaks. Proton MRS was able to demonstrate a statistically significant difference between HIV-infected subjects and controls. The marker/Cr was the best ratio to separate patients from controls, with controls having a mean ratio of 0.50 ± 0.51 and patients having a mean ratio of 1.8 ± 0.85 (p = 0.001). There was no difference between HIV-infected subjects with and without a history of IDU. No significant relationship was found between either neuropsychological test scores or CD4 count and metabolite ratios. In brief, MRS seems more sensitive than magnetic resonance imaging (MRI), being able to detect abnormalities in HIV-infected patients when imaging is normal.
AB - The purpose of our study was to determine whether proton magnetic resonance spectroscopy (MRS) could detect early brain involvement by human immunodeficiency virus (HIV). We recruited 19 asymptomatic HIV-infected patients, 9 with and 10 without a history of intravenous drug use (IDU), as well as 10 control subjects. All subjects had to have normal MR imaging to be enrolled. We identified the following peaks on proton MRS: n-acetyl aspartate, creatine, choline, and a conglomerate amino acid peak between 2.1 and 2.6 parts per million that we call the marker peaks. Proton MRS was able to demonstrate a statistically significant difference between HIV-infected subjects and controls. The marker/Cr was the best ratio to separate patients from controls, with controls having a mean ratio of 0.50 ± 0.51 and patients having a mean ratio of 1.8 ± 0.85 (p = 0.001). There was no difference between HIV-infected subjects with and without a history of IDU. No significant relationship was found between either neuropsychological test scores or CD4 count and metabolite ratios. In brief, MRS seems more sensitive than magnetic resonance imaging (MRI), being able to detect abnormalities in HIV-infected patients when imaging is normal.
KW - HIV
KW - Magnetic resonance spectroscopy
UR - http://www.scopus.com/inward/record.url?scp=0029959304&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029959304&partnerID=8YFLogxK
U2 - 10.1097/00042560-199611010-00006
DO - 10.1097/00042560-199611010-00006
M3 - Article
C2 - 8898669
AN - SCOPUS:0029959304
SN - 1525-4135
VL - 13
SP - 247
EP - 253
JO - Journal of Acquired Immune Deficiency Syndromes
JF - Journal of Acquired Immune Deficiency Syndromes
IS - 3
ER -